Bronchial asthma, chronic obstructive pulmonary disease and NF-κB

Current Medicinal Chemistry

Volumn 16, Issue 7, 2009, Pages 867-883

  Charokopos, Nikolaos ^a   Apostolopoulos, Nikolaos ^a   Kalapodi, Maria ^a   Leotsinidis, Michael ^b   Karamanos, Nikolaos ^c   Mouzaki, Athanasia ^c  

^a Department of Pulmonology   (Greece)

^b UNIVERSITY OF PATRAS   (Greece)

^c UNIVERSITY OF PATRAS   (Greece)

Author keywords

[No Author keywords available]

Indexed keywords

2 OXO 4 THIAZOLIDINECARBOXYLIC ACID; ACTIVATED PROTEIN C; ANTIHISTAMINIC AGENT; AROMATIC HYDROCARBON RECEPTOR; BETA 2 ADRENERGIC RECEPTOR STIMULATING AGENT; BRADYKININ ANTAGONIST; BUDESONIDE; CHOLINERGIC RECEPTOR BLOCKING AGENT; CIGLITAZONE; CORTICOSTEROID; FENOFIBRATE; FLUTICASONE PROPIONATE; FORMOTEROL; HISTONE DEACETYLASE INHIBITOR; HYALURONIC ACID; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; I KAPPA B; IMMUNOGLOBULIN E ANTIBODY; IMMUNOGLOBULIN ENHANCER BINDING PROTEIN; LEUKOTRIENE RECEPTOR BLOCKING AGENT; LYSOPHOSPHATIDIC ACID; MIFEPRISTONE; N (2 BENZOYLPHENYL) O [2 (METHYL 2 PYRIDINYLAMINO)ETHYL]TYROSINE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; SALMETEROL; STEROID; THEOPHYLLINE; TROGLITAZONE; TUMOR NECROSIS FACTOR ALPHA ANTIBODY; UNINDEXED DRUG;

ALLERGIC ASTHMA; ANTIINFLAMMATORY ACTIVITY; ANTIOXIDANT ACTIVITY; ASTHMA; CHRONIC OBSTRUCTIVE LUNG DISEASE; CLINICAL TRIAL; DRUG POTENTIATION; DRUG TARGETING; HUMAN; INFLAMMATION; LUPUS ERYTHEMATOSUS; NONHUMAN; OXIDATIVE STRESS; REVIEW; RHEUMATOID ARTHRITIS; RISK FACTOR; T LYMPHOCYTE;

ANIMALS; ASTHMA; HUMANS; NF-KAPPA B; PULMONARY DISEASE, CHRONIC OBSTRUCTIVE;

EID: 65649132348     PISSN: 09298673     EISSN: None     Source Type: Journal    
DOI: 10.2174/092986709787549280     Document Type: Review

References (150)

1. Barnes, P.J.; Shapiro, S.D.; Pauwels, R.A. Chronic obstructive pulmonary disease: Molecular and cellular mechanisms. Eur. Respir. J., 2003, 22, 672-688.
2. Piva, R.; Belardo, G.; Santoro, M.G. NF-κB: A Stress-Regulated Switch for Cell Survival. Antioxid. Redox Signal., 2006, 8, 478-486.
3. Li, N.; Karin, M. Is NF-kappaB the sensor of oxidative stress? FASEB J., 1999, 13, 1137-1143.
4. Tetley, T.D. Inflammatory cells and chronic obstructive pulmonary disease. Curr. Drug Target Inflamm. Allergy, 2005, 4, 607-618.
5. Sen, R.; Baltimore, D. Multiple nuclear factors interact with the immunoglobulin enhancer sequences. Cell, 1986, 46, 705-716.
6. Park, G.Y.; Christman, J.W. Nuclear Factor Kappa B is a Promising Therapeutic Target in Inflammatory Lung Disease. Curr. Drug Target, 2006, 7, 661-668.
7. Tergaonkar, V. NFκB pathway: A good signaling paradigm and therapeutic target. Int. J. Biochem. Cell Biol., 2006, 38, 1647-1653.
8. Hoffmann, A.; Levchenko, A.; Scott, M.L.; Baltimore, D. The IκBNF-κB signaling module: Temporal control and selective gene activation. Science, 2002, 298, 1241-1245
9. Kardos, P.; Keenan, J. Tackling COPD: A Multicomponent Disease Driven by Inflammation. MedGenMed., 2006, 8, 54.
10. Hogg, J.C. Pathophysiology of airflow limitation in chronic obstructive pulmonary disease. Lancet, 2004, 364, 709-721.
11. Rahman, I. Oxidative stress in pathogenesis of chronic obstructive pulmonary disease: Cellular and molecular mechanisms. Cell Biochem. Biophys., 2005, 43, 167-188.
12. MacNee, W. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol., 2001, 429, 195-207.
13. Parmentier, M.; Hirani, N.; Rahman, I.; Donalson, K.; MacNee, W.; Antonicelli, F. Regulation of lipopolysaccharide-mediated interleukin- 1beta release by N-acetylcysteine in THP-1 cells. Eur. Respir. J., 2000, 16, 933-939.
14. Barnes, P.J. Mediators of chronic obstructive pulmonary disease. Pharmacol. Rev., 2004, 56, 515-548.
15. Di Stefano, A.; Caramori, G.; Ricciardolo, F.L; Capelli, A.; Adcock, I.M.; Donner, C.F. Cellular and molecular mechanisms in chronic obstructive pulmonary disease: An overview. Clin. Exp. Allergy, 2004, 34, 1156-1167.
16. Shipley, J.M.; Wesselschmidt, R.L.; Kobayashi, D.K. Metalloelastase is required for macrophage-mediated proteolysis and matrix invasion in mice. Proc. Natl. Acad. Sci. USA., 1996, 93, 3942-3946.
17. Shapiro, S.D.; Goldstein, N.M.; Houghton, A.M.; Kobayashi, D.K.; Kelley, D.; Belaaouaj, A. Neutrophil elastase contributes to cigarette smoke-induced emphysema in mice. Am. J. Pathol., 2003, 163, 2329-2335.
18. Holgate, S.T.; Davies, D.E.; Powell, R.M.; Howarth, P.H.; Haitchi, H.M.; Holloway, J.W. Local genetic and environmental factors in asthma disease pathogenesis: Chronicity and persistence mechanisms. Eur. Respir. J., 2007, 29, 793-803.
19. Fixman, E.D.; Stewart, A.; Martin, J.G. Basic mechanisms of development of airway structural changes in asthma. Eur. Respir. J., 2007, 29, 379-389.
20. Yamamoto, Y.; Gaynor, R.B. Therapeutic potential of inhibition of the NF-κB pathway in the treatment of inflammation and cancer. J. Clin. Invest., 2001, 107, 135-142.
21. Chen, F.; Demers L.M.; Shi, X. Upstream Signal Transduction of NF-κB Activation. Curr. Drug Target Inflamm. Allergy, 2002, 1, 137-149.
22. MacNee, W. Oxidative stress and lung inflammation in airways disease. Eur. J. Pharmacol., 2001, 429, 195-207.
23. Bowler, R.P.; Crapo, J.D. Oxidative stress in airways: Is there a role for extracellular superoxide dismutase? Am. J. Respir. Crit. Care. Med., 2002, 166, 38-43.
24. Rahman, I. Oxidative Stress and Gene Transcription in Asthma and Chronic Obstructive Pulmonary Disease: Antioxidant Therapeutic Targets. Curr. Drug Target Inflamm. Allergy, 2002; 1, 291-315.
25. Rahman, I. Antioxidant therapies in COPD. Int. J. Chron. Obstruct. Pulmon. Dis., 2006, 1, 15-29.
26. Lee, Y.C.; Lee, K.S.; Park, S.J.; Park, H.S.; Lim, J.S.; Park, K.H.; Im, M-J.; Choi, I-W.; Lee, H-K.; Kim, U-H. Blockade of airway hyperresponsiveness and inflammation in a murine model of asthma by a prodrug of cysteine, L-2-oxothiazolidine-4-carboxylic acid. FASEB J., 2004, 18, 1917-1919.
27. Ardite, E.; Barbera, J.A.; Roca, J.; Fernandez-Checa, J. Glutathione depletion impairs myogenic differentiation of murine skeletal muscle C2C12 cells through sustained NF-κB activation. Am. J. Pathol., 2004, 165, 719-728.
28. Martinez-Losa, M.; Cortijo, J.; Juan, G.; Ramon, M.; Sanz, M.J.; Morcillo, E.J. Modulatory effects of N-acetyl-L-cysteine on human eosinophil apoptosis. Eur. Respir. J., 2007, 30, 436-442.
29. Lee, K.S.; Park, H.S.; Park, S.J.; Kim, S.R.; Min, K.H.; Jin, S.M.; Li, L.; Lee, Y.C. An antioxidant modulates expression of receptor activator of NF-κB in asthma. Exp. Mol. Med., 2006, 38, 217-229.
30. Ricciardolo, F.; Nijkamp, F.; Folkerts, G. Nitric oxide synthase (NOS) as therapeutic target for asthma and chronic obstructive pulmonary disease. Curr. Drug Target, 2006, 7, 721-735.
31. Tuder, R.M.; Yoshida, T.; Fijalkowka, I.; Biswal, S.; Petrache, I. Role of lung maintenance program in the heterogeneity of lung destruction in emphysema. Proc. Am. Thorac. Soc., 2006, 3, 673-679.
32. Yang, S.R.; Chida, A.S.; Bauter, M.R.; Shafiq, N.; Seweryniak, K.; Maggirwar, S.B.; Kilty, I.; Rahman, I. Cigarette smoke induces proinflammatory cytokine release by activation of NF-κB and post-translational modifications of histone deacetylase in macrophages. Am. J. Physiol. Lung Cell Mol. Physiol., 2006, 291, 46-57.
33. Kinnula, V.L. Focus on antioxidant enzymes and antioxidant strategies in smoking related airway diseases. Thorax, 2005, 60, 693-700.
34. Mossman, B.T.; Lounsbury, K.M.; Reddy, S.P. Oxidants and signaling by mitogen-activated protein kinases in lung epithelium. Am. J. Respir. Cell Mol. Biol., 2006, 34, 666-669.
35. Barnes, P.J. Transcription factors in airway diseases. Lab. Invest., 2006, 86, 867-872.
36. Szulakowski, P.; Crowther, A.J.; Jimenez, L.A.; Donaldson, K.; Mayer, R.; Leonard, T.B.; Macnee, W.; Drost, E.M. The effect of smoking on the transcriptional regulation of lung inflammation in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2006, 174, 41-50.
37. Sato, T.; Seyama, K.; Sato, Y.; Mori, H.; Souma, S.; Akiyoshi, T.; Kodama, Y.; Mori, T.; Goto, S.; Takahashi, K. Senescence marker protein-30 protects mice lungs from oxidative stress, aging, and smoking. Am. J. Respir. Crit. Care Med., 2006, 174, 530-537.
38. Henderson, W.R.; Chi, E.Y.; Teo, J.L.; Nguyen, C.; Kahn, M. A small molecule inhibitor of redox-regulated NF-κB and activator protein-1 transcription blocks allergic airway inflammation in a mouse asthma model. J. Immunol., 2002, 169, 5294-5299.
39. Okamoto, T.; Ogiwara, H.; Hayashi, T.; Mitsui, A.; Kawabe, T.; Yodoi, J. Human thioredoxin/adult T cell leukemia-derived factor activates the enhancer binding protein of human immunodeficiency virus type 1 by thiol redox control mechanism. Int. Immunol., 1992, 4, 811-819.
40. Ekstrand-Hammarstrom, B.; Österlund, C.; Lilliehöök, B.; Bucht, A. Vitamin E down-modulates mitogen-activated protein kinases, nuclear factor-κB and inflammatory responses in lung epithelial cells. Clin. Exp. Immunol., 2007, 147, 359-369
41. Sridhar, A.V.; McKean, M. Nedocromil sodium for chronic asthma in children. Cochrane Database Syst. Rev., 2006, 19, CD004108.
42. Broide, D.H.; Lawrence, T.; Doherty, T.; Cho, J.Y.; Miller, M.; McElwain, K.; McElwain, S.; Karin, M. Allergen-induced peribronchial fibrosis and mucus production mediated by IκB kinase beta-dependent genes in airway epithelium. Proc. Natl. Acad. Sci. USA., 2005, 102, 17723-17728.
43. Mercurio, F.; Zhu, H.; Murray, B.W.; Shevchenko, A.; Bennett, B.L.; Li, J.; Young, D.B.; Barbosa, M.; Mann, M.; Manning, A.; Rao, A. IKK-1 and IKK-2: Cytokine-activated IkappaB kinases essential for NF-κB activation. Science, 1997, 278, 860-866.
44. Hu, Y.; Baud, V.; Delhase, M.; Zhang, P.; Deerinck, T.; Ellisman, M.; Johnson, R.; Karin, M. Abnormal morphogenesis but intact IKK activation in mice lacking the IKKα subunit of IκB kinase. Science, 1999, 284, 316-320.
45. Li, L.; Xia, Y.; Nguyen, A.; Lai, Y.H.; Feng, L.; Mosmann, T.R.; Lo, D. Effects of Th2 cytokines on chemokine expression in the lung: IL-13 potently induces eotaxin expression by airway epithelial cells. J. Immunol., 1999, 162, 2477-2487.
46. Kishore, N.; Sommers, C.; Mathialagan, S.; Guzova, J.; Yao, M.; Hauser, S.; Huynh, K.; Bonar, S.; Mielke, C.; Albee, L.; Weier, R.; Graneto, M.; Hanau, C.; Perry, T.; Tripp, C. S. A selective IKK-2 inhibitor blocks NF-κB-dependent gene expression in interleukin-1 β-stimulated synovial fibroblasts. J. Biol. Chem., 2003, 278, 32861-32871.
47. Birrell, M.A.; Hardaker, E.; Wong, S.; McCluskie, K.; Catley, M.; De Alba, J.; Newton, R.; Haj-Yahia, S.; Pun, K.T.; Watts C.J.; Shaw, R.J.; Savage, T.J.; Belvisi, M.G. IκB Kinase-2 Inhibitor Blocks Inflammation in Human Airway Smooth Muscle and a Rat Model of Asthma. Am. J. Respir. Crit. Care Med., 2005, 172, 962-971
48. Newton, R.; Holden, N.S.; Catley, M.C.; Oyelusi, W.; Leigh, R.; Proud, D.; Barnes, P.J. Repression of inflammatory gene expression in human pulmonary epithelial cells by small-molecule IκB kinase inhibitors. J. Pharmacol. Exp. Ther., 2007, 321, 734-742.
49. Keslacy, S.; Tliba, O.; Baidouri, H.; Amrani, Y. Inhibition of tumor necrosis factor-α-inducible inflammatory genes by interferon-γ is associated with altered nuclear factor-κB transactivation and enhanced histone deacetylase activity. Mol. Pharmacol., 2007, 71, 609-618.
50. Sizemore, N.; Agarwal, A.; Das., K.; Lerner, N.; Sulak, M.; Rani, S.; Ransohoff, R.; Shultz, D.; Stark, G.R. Inhibitor of κB kinase is required to activate a subset of interferon γ-stimulated genes. Proc. Natl. Acad. Sci. USA., 2004, 101, 7994-7998
51. Kalesnikoff, J.; Baur, N.; Leitges, M.; Hughes, M.; Damen, J.E.; Huber, M.; Krystal, G. The role of SHIP in mast cell degranulation and IgE-induced mast cell survival. J. Immunol., 2002, 16, 4737-746.
52. Marquardt, D.L.; Walker, L.L. Dependence of mast cell IgE-mediated cytokine production on nuclear factor-κB activity. J. Allergy Clin. Immunol., 2000, 105, 500-505.
53. Peng, Y.; Power, M.R.; Li, B.; Lin, T.J. Inhibition of IKK down-regulates antigen + IgE-induced TNF production by mast cells: A role for the IKK-IκB-NF-κB pathway in IgE-dependent mast cell activation. J. Leukoc. Biol., 2005, 77, 975-983
54. Karin, M.; Lin, A. NF-κB at the crossroads of life and death. Nat. Immunol., 2002, 3, 221-227.
55. Bousquet, J.; Jeffery, P.K.; Busse, W.W.; Johnson, M.; Vignola, A.M. Asthma. From bronchoconstriction to airways inflammation and remodeling. Am. J. Respir. Crit. Care Med., 2000, 161, 1720-1745.
56. Senftleben, U.; Li, Z.W.; Baud, V.; Karin, M. IKKβ is essential for protecting T cells from TNFα-induced apoptosis. Immunity, 2001, 14, 217-230.
57. Montagut, C.; Rovira, A.; Albanell, J. The proteasome: A novel target for anticancer therapy. Clin. Transl. Oncol., 2006, 8, 313-317.
58. Olivier, S.; Robe, P.; Bours, V. Can NF-κB be a target for novel and efficient anti-cancer agents? Biochem. Pharmacol., 2006, 72, 1054-1068.
59. Broide, D.H. Immunologic and inflammatory mechanisms that drive asthma progression to remodelling. J. Allergy Clin. Immunol., 2008, 121, 560-570.
60. Barnes, P.J. Corticosteroid effects on cell signalling. Eur. Respir. J., 2006, 27, 413-426.
61. Wilson, S.J.; Wallin, A.; Della-Cioppa, G.S.; Holgate, S.T. Effects of budesonide and formoterol on NF-κB, adhesion molecules, and cytokines in asthma. Am. J. Respir. Crit. Care Med., 2001, 164, 1047-1052.
62. Baouz, S.; Giron-Michel, J.; Azzarone, B.; Giuliani, M.; Cagnoni, F.; Olsson, S.; Testi, R.; Gabbiani, G.; Canonica, G.W. Lung myo-fibroblasts as targets of salmeterol and fluticasone propionate: Inhibition of α-SMA and NF-κB. Int. Immunol., 2005, 17, 1473-1481.
63. Silverman, E.S.; Liggett, S.B.; Gelfand, E.W.; Rosenwasser, L.J.; Baron, R.M.; Bolk, S.; Weiss, S.T.; Drazen, J.M. The pharmacogenetics of asthma: A candidate gene approach. Pharmacogenomics J., 2001, 1, 27-37.
64. Yuda, H.; Adachi, Y.; Taguchi, O.; Gabazza, E.; Hataji, O.; Fujimoto, H.; Tamaki, S.; Nishikubo, K.; Fukudome, K.; D'Alessandro-Gabazza, C.N.; Maruyama, J.; Izumizaki, M.; Iwase, M.; Homma, I.; Inoue, R.; Kamada, H.; Hayashi, T.; Kasper, M.; Lambrecht, B.N.; Barnes, P.J.; Suzuki, K. Activated protein C inhibits bronchial hyperresponsiveness and Th2 cytokine expression in mice. Blood, 2004, 3, 2196-2204.
65. Zhao, Y.; Usatyuk, P.V.; Cummings, R.; Saatian, B.; He, D.; Watkins, T.; Morris, A.; Spannhake, E.W.; Brindley, D.N.; Natarajan, V. Lipid phosphate phosphatase-1 regulates lysophosphatidic acid-induced calcium release, NF-κB activation and interleukin-8 secretion in human bronchial epithelial cells. Biochem. J., 2005, 15, 493-502.
66. Popescu, F.D. Antisense- and RNA interference-based therapeutic strategies in allergy. J. Cell Mol. Med., 2005, 9, 840-853.
67. Bao, Z.;Lim, S.; Liao, W.; Lin, Y.; Thiemermann, C.; Lenng, B.P.; Wong, W.S. Glycogen synthase kinase-3β inhibition attenuates asthma in mice Am. J. Resp. Crit. Care Med., 2007, 176, 431-438.
68. Nakamura, H.; Aoki, M.; Tamai, K.; Oishi, M.; Ogihara, T.; Kaneda, Y.; Morishita, R. Prevention and regression of atopic dermatitis by ointment containing NF-κB decoy oligodeoxynucleotides in NC/Nga atopic mouse model. Gene Ther., 2002, 9, 1221-1229.
69. Blanchard, F.; Chipoy, C. Histone deacetylase inhibitors: New drugs for the treatment of inflammatory diseases? Drug Disc. Today, 2005, 10, 197-204.
70. Global Strategy for the Diagnosis Management and prevention of chronic obstructive pulmonary disease (Updated 2007) www.goldcopd.org.
71. Wouters, E.F.; Creutzberg, E.C.; Schols, A.M. Systemic effects in COPD. Chest, 2002, 121, 127-130.
72. Agusti, A.G.; Noguera, A.; Sauleda, J.; Sala, E.; Pons, J.; Busquets, X. Systemic effects of chronic obstructive pulmonary disease. Eur. Respir. J., 2003, 21, 347-360.
73. Balasubramanian, V.P.; Varkey, B. Chronic obstructive pulmonary disease: effects beyond the lungs. Curr. Opin. Pulm. Med., 2006, 12, 106-112.
74. Langen, R.C.; Schols, A.M.; Kelders, M.C.; Wouters, E.F.; Janssen-Heininger, Y.M. Inflammatory cytokines inhibit myogenic differentiation through activation of nuclear factor-κB. FASEB J., 2001 1169-1180.
75. Buck, M.; Chojkier, M. Muscle wasting and dedifferentiation induced by oxidative stress in a murine model of cachexia is prevented by inhibitors of nitric oxide synthesis and antioxidants. EMBO J., 1996, 15, 1753-1765.
76. Ito, K.; Ito, M.; Elliott, W.M.; Cosio, B.; Caramori, G.; Kon, O.M. Decreased histone deacetylase activity in chronic obstructive pulmonary disease. N. Engl. J. Med., 2005, 352, 1967-1976
77. Agusti, A.; Morla, M.; Sauleda, J.; Saus, C.; Busquets, X. NF-κB activation and iNOS upregulation in skeletal muscle of patients with COPD and low body weight. Thorax, 2004, 59, 483-487.
78. Cai, D.; Frantz, J.D.; Tawa, N.E.; Melendez, P.A.; Oh, B.C.; Lidov, H.G.; Hasselgren, P.O.; Frontera, W.R.; Lee, J.; Glass, D.J.; Shoelson, S.E. IKKβ/NF-κB activation causes severe muscle wasting in mice. Cell, 2004, 119, 285-288.
79. Patel, H.J.; Belvisi, M.G.; Bishop-Bailey, D.; Yacoub, M.H.; Mitchell, J.A. Activation of peroxisome proliferator-activated receptors in human airway smooth muscle cells has a superior antiinflammatory profile to corticosteroids: Relevance for chronic obstructive pulmonary disease therapy. J. Immunol., 2003, 170, 2663-2669.
80. Muoio, D.M.; MacLean, P.S.; Lang, D.B.; Li, S.; Houmard, J.A.; Way, J.M.; Winegar, D.A.; Corton, J.C.; Dohm, G.L.; Kraus, W.E. Fatty acid homeostasis and induction of lipid regulatory genes in skeletal muscles of peroxisome proliferator-activated receptor (PPAR) α knock-out mice. Evidence for compensatory regulation by PPAR δ. J. Biol. Chem., 2002, 277, 26089-26097.
81. Delayre-Orthez, C.; Becker, J.; Guenon, I.; Lagente, V.; Auwerx, J.; Frossard, N.; Pons, F. PPARα downregulates airway inflammation induced by lipopolysaccharide in the mouse. Respir. Res., 2005, 6, 91.
82. Poynter, M.E.; Daynes, R.A. Peroxisome proliferator-activated receptor alpha activation modulates cellular redox status, represses nuclear factor-κB signaling, and reduces inflammatory cytokine production in aging. J. Biol. Chem., 1998, 273, 32833-32841
83. Staels, B.; Koenig, W.; Habib, A.; Merval, R.; Lebret, M.; Torra, I.P.; Delerive, P.; Fadel, A.; Chinetti, G.; Fruchart, J.C.; Najib, J.; Maclouf, J.; Tedgui, A. Activation of human aortic smooth-muscle cells is inhibited by PPARα but not by PPARγ activators. Nature, 1998, 393, 790-793.
84. Takahashi, M.; Tsuboyama-Kasaoka, N.; Nakatani, T. Fish oil feeding alters liver gene expressions to defend against PPARα activation and ROS production. Am. J. Physiol. Gastrointest. Liver Physiol., 2002, 282, 338-348.
85. Toyama, T.; Nakamura, H.; Harano, Y.; Yamauchi, N.; Morita, A.; Kirishima, T.; Minami, M.; Itoh, Y.; Okanoue. T. PPARα ligands activate antioxidant enzymes and suppress hepatic fibrosis in rats. Biochem. Biophys. Res. Commun., 2004, 324, 697-704
86. Kersten, S.; Desvergne, B.; Wahli, W. Roles of PPARs in health and disease. Nature, 2000, 405, 421-424.
87. Spears, M.; McSharry, C.; Thomson, N.C. Peroxisome proliferator-activated receptor-γ agonists as potential anti-inflammatory agents in asthma and chronic obstructive pulmonary disease. Clin. Exp. Allergy, 2006, 36, 1494-1504
88. Rieusset, J.; Touri, F.; Michalik, L.; Escher, P.; Desvergne, B.; Niesor, E.; Wahli, W. A new selective peroxisome proliferator-activated receptor γ antagonist with antiobesity and antidiabetic activity. Mol. Endocrinol., 2002, 16, 2628-2644.
89. Verges, B. Clinical interest of PPARs ligands. Diab. Metab., 2004, 30, 7-12.
90. Akiyama, T.E.; Meinke, P.T.; Berger, J.P. PPAR ligands: Potential therapies for metabolic syndrome. Curr. Diab. Rep., 2005, 5, 45-52.
91. Broekhuizen, R.; Wouters, E.F.; Creutzberg, E.C.; Weling-Scheepers, C.A.; Schols, A.M. Polyunsaturated fatty acids improve exercise capacity in chronic obstructive pulmonary disease. Thorax, 2005, 60, 376-382.
92. Benayoun, L.S.; Letuve, A.; Druilhe, J.; Boczkowski, M.C.; Dombret, P.; Mechighel, J.; Megret, G.; Leseche, M.; Aubier, M.; Pretolani, M. Regulation of peroxisome proliferator-activated receptor gamma expression in human asthmatic airways: Relationship with proliferation, apoptosis, and airway remodeling. Am. J. Respir. Crit. Care Med., 2001, 164, 1487-1494.
93. Wang, A.C.; Dai, X.; Luu, B.; Conrad, D.J. Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am. J. Respir. Cell Mol. Biol., 2001, 24, 688-693.
94. Hammad, H.; Jan de Heer, H.; Soullie, T.; Angeli, V.; Trottein, F.; Hoogsteden, H.; Lambrecht, B.N. Activation of peroxisome proliferator-activated receptor-gamma in dendritic cells inhibits the development of eosinophilic airway inflammation in a mouse model of asthma. Am. J. Pathol., 2004, 164, 263-271.
95. Kyung, S.L.; Seoung, J.; Park, S.; Ri, K.; Kyung, H.M.; Sun, M.J.; Hern, K.L.; Yong, C.L. Modulation of airway remodeling and airway inflammation by peroxisome proliferator-activated receptor gamma in a murine model of toluene diisocyanate-induced asthma. J. Immunol., 2006, 177, 5248-5257.
96. August, A.; Mueller, C.; Weaver, V.; Polanco, T.; Walsh, E.; Cantorna, M. Nutrients, nuclear receptors, inflammation, immunity lipids, PPAR, and allergic asthma. J. Nutr., 2006, 136, 695-699.
97. Kling, S.; Donninger, H.; Williams, Z.; Vermeulen, J.; Weinberg, E.; Latiff, K.; Ghildyal, R.; Bardin, P. Persistence of rhinovirus RNA after asthma exacerbation in children. Clin. Exp. Allergy, 2005, 35, 672-678.
98. Heymann, P.W.; Carper, H.T.; Murphy, D.D.; Platts-Mills, T.A.; Patrie, J.; McLaughlin, A.P.; Erwin, E.A.; Shaker, M.S.; Hellems, M.; Peerzada, J.; Hayden, F.G.; Hatley, T.K.; Chamberlain, R. J. Viral infections in relation to age, atopy, and season of admission among children hospitalized for wheezing. Allergy Clin. Immunol., 2004, 114, 239-247.
99. Mallia, P.; Johnston, S.L. How viral infections cause exacerbation of airway diseases. Chest, 2006, 130, 1203-1210.
100. Arnold, R.; Koening, W. Peroxisome-proliferator-activated receptor-γ agonists inhibit the release of proinflammatory cytokines from RSV-infected epithelial cells. Virology, 2006, 346, 427-439.
101. Luquet, S.; Gaudel, C.; Holst, D.; Lopez-Soriano, J.; Jehl-Pietri, C.; Fredenrich, A.; Grimaldi, P.A. Roles of PPAR δ in lipid absorption and metabolism: A new target for the treatment of type 2 diabetes. Biochim. Biophys. Acta, 2005, 1740, 313-317.
102. Fredenrich, A.; Grimaldi, P.A. Roles of peroxisome proliferator-activated receptor δ in skeletal muscle function and adaptation. Curr. Opin. Clin. Nutr. Metab. Care, 2004, 7, 377-381.
103. Remels, A.H.; Schrauwen, P.; Broekhuizen, R.; Willems, J.; Kersten, S.; Gosker, H.R.; Schols, A.M. Peroxisome proliferator-activated receptor expression is reduced in skeletal muscle in COPD. Eur. Respir. J., 2007, 30, 245-252.
104. Thatcher, T.H.; Maggirwar, S.B.; Baglole, C.J.; Lakatos, H.F.; Gasiewicz, T.A.; Phipps, R.P.; Sime, P.J. Aryl hydrocarbon receptor-deficient mice develop heightened inflammatory responses to cigarette smoke and endotoxin associated with rapid loss of the nuclear factor-κB component RelB. Am. J. Pathol., 2007, 170, 855-864.
105. Amon, A.; Pahl, A.; Szelenyi, I. Are there any realistic chances to develop new drugs for asthma? Drug News Perspect., 2006, 19, 189-200.
106. Adcock, IM.; Chung, K.F; Garamori, G.; Ito, K. Kinase inhibitors and airway inflammation. Eur. J.Pharmacol., 2006, 533, 118-132.
107. Nath, P.; Eynott, S.Y.; Adcock, I.M.; Bennett, B.L.; Chung, K.F. Potential role of c-Jun NH2-terminal kinase in allergic airway inflammation and remodelling: Effects of SP600125. Eur. J. Pharm., 2005, 506, 273-283.
108. Meltzer, E.O.; Berkowitz, R.B.; Grossbard, E.B. J. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. Allergy Immunol., 2005, 115, 791-796.
109. Matthew, E.; Poynter, R.C.; van Woerkom, T.; Butnor, K.J.; Vacek, P.; Taatjes, D.J; Irvin, C.G.; Janssen-Heininger, Y.M.W. NF-κB activation in airways modulates allergic inflammation but not hyperresponsiveness. J. Immunol., 2004, 173, 7003-7009.
110. Tsitoura, D.C.; Tassios, Y. Immunomodulation: The future cure for allergic diseases. Ann. N.Y. Acad. Sci., 2006, 1088, 100-115.
111. Garamori,G.; Groneberg, D.; Ito, K.; Gasolari, P.; Adcock, I.M.; Papi, A. New drugs targeting Th2 lymphocytes in asthma. J. Occup. Med. Toxicol., 2008, 3, S6.
112. Malhotra, D.; Thimmulappa, R.; Navas-Acien, A.; Sandford, A.; Elliott, M.; Singh, A.; Chen, L.; Zhuang, X.; Hogg, J.; Pare, P.; Tuder, RM.; Biswal, S. Decline in NRF2-regulated Antioxidants in Chronic Obstructive Pulmonary Disease Lungs Due to Loss of Its Positive Regulator, DJ-1. Am. J. Respir. Crit. Care Med., 2008, 15, 592-604.
113. Xrystakis, E.; Kusumakar, S.; Boswell, S.; Peek,E.;Urry, Z.; Richards, D.F.; Adikibi, T.; Pridgeon, C.; Dallman, M.; Loke, T.K.; Robinson, D.S.; Barrat, F.J.; O, Garra, A.; Lavender, P.; Corrigan, C.; Hawrylowicz, C.M. Reversing the defective induction of IL-10-secreting regulatory T cells in glucocorticoid-resistant asthma patients. J. Clin. Invest., 2006, 116, 146-155.
114. Burgel, P.R.; Nadel, J.A. Epidermal growth factor receptor-mediated innate immune responses and their roles in airway diseases. Eur. Respir. J., 2008, 32, 1068-1081.
115. Liu, K.; Gualano, R.; Hibbs, M.; Anderson, G.; Bozinovski, S. Rhinovirus uses EGFR signaling to coordinate IL-8 and ICAM-1 expression in bronchial epithelial cells. Eur. Respir. J., 2008, 32, S52.
116. Bergin, D.A.; Greeene, C.M.; Sterchi, E.E.; Kena, C.; Geraghty, P.; Tagart, C.C.; O' Neill, S.J.; McElvaney, N.G. J. Activation of EGFR by a novel metalloprotease pathway. Biol. Chem., 2008 (in press).
117. Sestini, P.; Renzoni, E.; Robinson, S.; Poole, P.; Ram, F.S. Shortacting beta 2 agonists for stable COPD. Cochrane Database Syst. Rev., 2003, CD001495.
118. Wilt, T.; Niewoher, G.; MacDonald, R.; Kane, R.L. Management of stable chronic obstructive pulmonary disease: A systematic review for a clinical practice guideline. Ann. Intern. Med., 2007, 147, 639.
119. Barnes, N.; Qiu, Y.S.; Pavord, I.D.; Parker, D.; Davis, P.A.; Zhu, J.; Johnson, M.; Thomson, N.C.; Jeffery, P.K. Antiinflammatory effects of salmeterol/fluticasone propionate in chronic obstructive lung disease. Am. J. Respir. Crit. Care Med., 2006, 173, 736-744.
120. Cardos, P.; Wencker, M.; Glaab, T.; Vogelmeier, C. Impact of salmeterol/ fluticasone propionate versus salmeterol on exacerbations in severe chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2007, 175, 144-149.
121. Rabe, K.F. Treating COPD--the TORCH trial, P values, and the Dodo. N. Engl. J.Med., 2007, 356, 851-854.
122. Walters, E.; Walters, J.A.; Gibson, M. Inhaled long acting beta agonists for stable chronic asthma. Cochrane Database Syst. Rev., 2003, CD001385.
123. NiChroinin, M.; Greenstone, I.R.; Ni Chroinin, M.N.; Masse, V.; Danish, A.; Magdalinos, H.; Zang, X.; Ducharme, F.M. Long-acting β2-agonists versus placebo in addition to inhaled corticosteroids in children and adults with chronic asthma. Cochrane Database Syst.Rev., 2005, 19, CD005533.
124. Joos, S.; Miksch, A.; Szecsenyi, J.; Wieseler, B.; Grouven, U.; Kaiser, T.; Schneider, A. Montelukast as add-on therapy to inhaled corticosteroids in the treatment of mild to moderate asthma: A systematic review. Thorax, 2008, 63, 453-462.
125. Zhou, Y.; Wang, X.; Zeng, X.; Qiu, R.; Xie, J.; Liu, S.; Zheng, J.; Zhong, N.; Ran, P. Positive benefits of theophylline in a randomized, double-blind, parallel-group, placebo-controlled study of lowdose, slow-release theophylline in the treatment of COPD for 1 year. Respirology, 2006, 11, 603-610.
126. Casale, T.B.; Stokes, J.R. Immunomodulators for allergic respiratory disorders. J. Allergy Clin. Immunol., 2008, 121, 288-289.
127. Brightling, C.; Berry, M.; Amrani Y. A novel therapeutic approach for asthma. J. Allergy Clin. Immunol., 2008, 121, 5
128. Smith, V.B.; Spina, D. Selective phosphodiesterase 4 inhibitors in the treatment of allergy and inflammation. Curr. Opin. Invest. Drugs, 2005, 6, 1136-1141.
129. Rennard, S.I.; Schachter, N.; Strek, M.; Rickard, K.; Amit, O. Cilomilast for COPD: Results of a 6-month, placebo-controlled study of a potent, selective inhibitor of phosphodiesterase 4. Chest, 2006, 129, 56-66.
130. Lehnigk, B.; Rabe, K.F.; Dent, G.; Herst, R.S.; Carpentier, P.J.; Magnussen, H. Effects of a 5-lipoxygenase inhibitor, ABT-761, on exercise-induced bronchoconstriction and urinary LTE4 in asthmatic patients. Eur. Respir. J., 1998, 11, 617-623.
131. Pilette, C.; Francis, J.N.; Till, S.J.; Durham, S.R. CCR4 ligands are up-regulated in the airways of atopic asthmatics after segmental allergen challenge. Eur. Respir. J., 2004, 23, 876-884.
132. Beier, K.C. ; Kallinich, T.; Hamelmann, E. T-cell co-stimulatory molecules: Novel targets for the treatment of allergic airway disease. Eur. Respir. J., 2007, 30, 383-390.
133. Matsuse, H., Kong, X., Hu, J.; Wolf, S.F.; Lockey, R.F.; Mohaparta, S.S. Intranasal IL-12 produces discreet pulmonary and systemic effects on allergic inflammation and airway reactivity. Int. Immunopharmacol., 2003, 3, 457-468.
134. Walsh, G.M. Targeting airway inflammation: Novel therapies for the treatment of asthma. Curr. Med. Chem., 2006, 13, 3105-3111.
135. Beeh, K.M.; Beier, J.; Meyer, M.; Buhl, R.; Zahlten, R.; Wolf, G. Bimosiamose, an inhaled small-molecule pan-selectin antagonist, attenuates late asthmatic reactions following allergen challenge in mild asthmatics: A randomized, double-blind, placebo-controlled clinical cross-over-trial. Pulm.Pharmacol. Ther., 2006, 19, 233-241.
136. Gomez, F.P.; Marrades, R.M.; Iglesia, R.; Roca, J.; Barbera, J.A.; Chung, K.F.; Rodriguez-Rosin, R.M. Gas exchange response to a PAF receptor antagonist, SR 27417A, in acute asthma: A pilot study. Eur. Respir. J., 1999, 14, 622-626.
137. Valenti, C.; Cialdai, C.; Giuliani, S.; Tramontana, M.; Quartara, L.; Maggi, C.A. Eur. J. Pharmacol., 2008, 579, 350
138. Flood-Page, P.; Swenson, C.; Faiferman, I.; Matthews, J.; Williams, M.; Brannick, L.; Robinson, D.; Wenzel, S.; Busse, W.; Hansel, T.T.; Barnes, N.C. International Mepolizumab Study Group. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med., 2007, 176, 1062-1071.
139. O'Byrne, P.M. Cytokines or their antagonists for the treatment of asthma. Chest, 2006, 130, 244-250.
140. Yamagata, T.; Ichinose, M. Agents against cytokine synthesis or receptors. Eur. J. Pharmacol., 2006, 8, 289-301
141. Van der Vaart, H.; Koeter, G.H.; Postma, D.S.; Kauffman, H.F.; ten Hacken, N.H. First study of infliximab treatment in patients with chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med., 2005, 172, 465-469.
142. ] Ravensberg, A.J.; Luijk, B.; Westers, P.; Hiemstra, P.S.; Sterk, P.J.; Lammers, J.W.; Rabe, K.F. The effect of a single inhaled dose of a VLA-4 antagonist on allergen-induced airway responses and airway inflammation in patients with asthma. Allergy, 2006, 61, 1097-1103.
143. Lee, D.K.; Gray, R.D.; Wilson, A.M.; Robb, F.M.; Soutar, P.C.; Lipworth, B.J. Single and short-term dosing effects of levocetirizine on adenosine monophosphate bronchoprovocation in atopic asthma. Br. J. Clin. Pharmacol., 2004, 58, 34-39.
144. Pettipher, R.; Hansel, T.T.; Armer, R. Antagonism of the prostaglandin D2 receptors DP1 and CRTH2 as an approach to treat allergic diseases. Nat. Rev. Drug. Discov., 2007, 6, 313-325.
145. Riccioni, G.; Bucciarelli, T.; Mancini, B.; Dillio, C.; D, Oranzio, N. Antileukotriene drugs: Clinical application, effectiveness and safety. Curr. Med. Chem., 2007, 14, 1966-1977.
146. Peter-Golden, M.; Henderson, W.R. Leukotrienes. N. Engl. J. Med., 2007, 357, 1841-1854.
147. Evans, D.J.; Barnes, P.J.; Spaethe, S.M.; vanAlstyne, E.L.; Mitchell, M.I.; O' Connor, B.J. Effect of a leukotriene B4 receptor antagonist, LY293111, on allergen induced responses in asthma. Thorax, 1996, 51, 1178-1184.
148. Smith, S.J.; Fenwick, P.S.; Nicholson, A.G.; Kirschenbaum, F.; Finney-Hayward, T.K.; Higgins, L.S.; Giembycz, M.A.; Barnes, P.J.; Donnelly, L.E. Inhibitory effect of p38 mitogen-activated protein kinase inhibitors on cytokine release from human macrophages. Br. J. Pharmacol., 2006, 149, 393-404.
149. Kunz, L.I.; van Rensen, E.L.; Sterk, P.J. Inhaled hyaluronic acid against exercise-induced bronchoconstriction in asthma. Pulm. Pharmacol. Ther., 2006, 19, 286-291.
150. Søyseth, V.; Brekke, P.H.; Smith, P.; Omland, T. Statin use is associated with reduced mortality in COPD. Eur. Respir. J., 2007, 29, 279-283.